Skip to main content
SpringerLink
Log in

Connective tissue diseases

Remission in SLE — are we there yet?

  • News & Views
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

The concept of treating to a target of remission is gaining ground in systemic lupus erythematosus. New research suggests that achievement of this treatment goal is rare, but are the definitions of remission used in these studies fit for purpose?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Treat to target, remission and low disease activity in SLE.

References

  1. van Vollenhoven, R. F. et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 73, 958–967 (2014).

    Article  Google Scholar 

  2. Franklyn, K., Hoi, A., Nikpour, M. & Morand, E. F. The need to define treatment goals for systemic lupus erythematosus. Nat. Rev. Rheumatol. 10, 567–571 (2014).

    Article  CAS  Google Scholar 

  3. Wilhelm, T. R., Magder, L. S. & Petri, M. Remission in systemic lupus erythematosus: durable remission is rare. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2016-209489 (2016).

  4. Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3–15 (2016).

    Article  Google Scholar 

  5. Apostolopoulos, D. & Morand, E. F. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford) (in press) (2016).

  6. Franklyn, K. et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann. Rheum. Dis. 75, 1615–1621 (2016).

    Article  CAS  Google Scholar 

  7. Zen, M. et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann. Rheum. Dis. 74, 2117–2122 (2015).

    Article  CAS  Google Scholar 

  8. Petri, M., Purvey, S., Fang, H. & Magder, L. S. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 64, 4021–4028 (2012).

    Article  CAS  Google Scholar 

  9. Furie, R. A. et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61, 1143–1151 (2009).

    Article  CAS  Google Scholar 

  10. Jolly, M. et al. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann. Rheum. Dis. 69, 29–33 (2009).

    Article  Google Scholar 

Download references

Acknowledgements

E.F.M. is a contributor to the Definitions of Remission in SLE (DORIS) working group and a member of the Asia-Pacific Lupus Collaboration (APLC).

Author information

Authors and Affiliations

  1. Monash University School of Clinical Sciences at Monash Health, Monash Medical Centre, Locked Bag No 29, Clayton, Melbourne, 3168, VIC, Australia

    Eric F. Morand

Authors
  1. Eric F. Morand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric F. Morand.

Ethics declarations

Competing interests

E.F.M. declares that he has received grants or research support from AstraZeneca, Janssen, GSK and UCB; received speaker's honoraria from UCB; and acted as a consultant for AstraZeneca and Pfizer.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morand, E. Remission in SLE — are we there yet?. Nat Rev Rheumatol 12, 696–698 (2016). https://doi.org/10.1038/nrrheum.2016.174

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2016.174

  • Springer Nature Limited

This article is cited by

Search

Navigation